What changed: Endometrial cancer
Every dated change on the records linked to Endometrial cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
July 2026 · 1
2026 · 2
2025 · 3
- 2025RegulatoryRinatabart sesutecanRinatabart sesutecan: designation granted (US)
Breakthrough Therapy designation, advanced endometrial cancer after PD-(L)1 and platinum
- 2025Trial resultRAINFOL-01 (Rina-S)RAINFOL-01 (Rina-S) reported
ORR 55.
- 2025MilestoneRinatabart sesutecanRina-S Breakthrough designation in endometrial cancer
A milestone in how this cancer is treated.
August 2024 · 1
2024 · 2
- 2024ApprovalDostarlimabDostarlimab approved in US
Primary advanced/recurrent endometrial cancer with chemotherapy (all-comers)
- 2024MilestonePembrolizumabAll-comers approvals: pembrolizumab (June), dostarlimab (August), durvalumab dMMR (June); T-DXd tumour-agnostic HER2 approval; RUBY overall survival benefit
A milestone in how this cancer is treated.
July 2023 · 1
2023 · 6
- 2023Trial resultDESTINY-PanTumor02DESTINY-PanTumor02 reported
Endometrial ORR 57.
- 2023Trial resultDUO-E / GOG-3041 / ENGOT-EN10DUO-E / GOG-3041 / ENGOT-EN10 reported
PFS HR 0.
- 2023Trial resultNRG-GY018 / KEYNOTE-868NRG-GY018 / KEYNOTE-868 reported
PFS HR 0.
- 2023Trial resultRUBY / ENGOT-EN6 / GOG-3031RUBY / ENGOT-EN6 / GOG-3031 reported
OS 44.
- 2023MilestoneRUBY / ENGOT-EN6 / GOG-3031RUBY, NRG-GY018, DUO-E: chemo-immunotherapy first line
Three trials in one year; dostarlimab approved for dMMR (July 2023).
- 2023MilestoneDostarlimabRUBY/NRG-GY018: IO first line
A milestone in how this cancer is treated.
July 2021 · 1
April 2021 · 1
2021 · 5
- 2021ApprovalDostarlimabDostarlimab approved in US
dMMR recurrent/advanced endometrial cancer; dMMR solid tumours
- 2021ApprovalLenvatinibLenvatinib approved in US
Advanced RCC with pembrolizumab; endometrial cancer with pembrolizumab
- 2021ApprovalVENTANA MMR RxDx PanelVENTANA MMR RxDx Panel approved in US
Companion diagnostic for dostarlimab in dMMR endometrial cancer
- 2021Trial resultKEYNOTE-775 / Study 309KEYNOTE-775 / Study 309 reported
OS 18.
- 2021MilestoneKEYNOTE-775 / Study 309KEYNOTE-775: lenvatinib + pembrolizumab OS benefit; dostarlimab approved for dMMR recurrence (GARNET); molecular classification enters ESGO guidelines
A milestone in how this cancer is treated.
September 2019 · 1
2019 · 1
2018 · 2
2017 · 2
2013 · 2
- 2013MilestoneEndometrial cancer molecular classes (POLEmut, MMRd, p53abn, NSMP)TCGA defines four molecular classes
POLE-ultramutated, MSI-hypermutated, copy-number low, copy-number high (p53-abnormal).
- 2013MilestoneEndometrial cancerTCGA molecular classification
A milestone in how this cancer is treated.
2010 · 1
2009 · 1
1983 · 1
1971 · 2
- 1971ApprovalProgestins (megestrol acetate, medroxyprogesterone, levonorgestrel IUD)Progestins (megestrol acetate, medroxyprogesterone, levonorgestrel IUD) approved in US
Palliative treatment of advanced endometrial and breast cancer (megestrol)
- 1971MilestoneProgestins (megestrol acetate, medroxyprogesterone, levonorgestrel IUD)Progestins approved for advanced endometrial cancer
A milestone in how this cancer is treated.